Effect of Revulsive Compresses on Knee Associated Symptoms and Pain Severity among Patients with Knee osteoarthritis

Abstract Knee osteoarthritis (KOA) is one of the most prominent causes of chronic pain, functional impairment, and disability in older adults. The current standards of care for KOA are aimed toward reducing pain and are largely comprised of analgesic medications, but existing pharmacologic approaches often produce significant adverse effects. Moreover, recent evidence suggests that KOA pain is characterized by alterations in pain-related brain mechanisms. Cranial electrical stimulation (CES), which delivers a low-amplitude alternating electric current to the brain, can facilitate the reversal of maladaptive brain function. Portable CES devices can be used at home with real-time monitoring through a secure videoconferencing platform to facilitate high adherence. Thus, the purpose of this pilot clinical study was to examine the preliminary efficacy of remotely supervised CES on clinical pain severity in older adults with KOA. Thirty participants with KOA were randomly assigned to receive 10 daily sessions of remotely supervised CES with 0.1 mA at a frequency of 0.5 Hz for 60 minutes (n=15) or sham CES (n=15). We measured clinical pain severity using the numeric rating scale (NRS; range, 0 – 100). Participants (67% female) had a mean age of 59 years. Active CES significantly reduced scores on the NRS (Cohen’s d = 1.43, P < 0.01). Participants tolerated CES well without any adverse events. Our findings demonstrate the promising clinical efficacy of remotely supervised CES for older adults with KOA. Future studies with larger-scale randomized controlled trials with follow-up assessments are needed to validate and extend our findings.

Download Full-text

The association between knee joint biomechanics and neuromuscular control and moderate knee osteoarthritis radiographic and pain severity

Osteoarthritis and Cartilage ◽

10.1016/j.joca.2010.10.020 ◽

2011 ◽

Vol 19 (2) ◽

pp. 186-193 ◽

Cited By ~ 61

Author(s):

J.L. Astephen Wilson ◽

K.J. Deluzio ◽

M.J. Dunbar ◽

G.E. Caldwell ◽

C.L. Hubley-Kozey

Keyword(s):

Knee Joint ◽

Knee Osteoarthritis ◽

Neuromuscular Control ◽

Pain Severity ◽

Joint Biomechanics

Download Full-text

Comparison of Rizatriptan 5 mg and 10 mg Tablets and Sumatriptan 25 mg and 50 mg Tablets

Cephalalgia ◽

10.1111/j.1468-2982.2004.00707.x ◽

2004 ◽

Vol 24 (7) ◽

pp. 540-546 ◽

Cited By ~ 20

Author(s):

A Kolodny ◽

A Polis ◽

WP Battisti ◽

L Johnson-Pratt ◽

F Skobieranda ◽

...

Keyword(s):

Pain Relief ◽

Odds Ratio ◽

Acute Treatment ◽

Functional Disability ◽

Statistical Significance ◽

Pain Severity ◽

Double Blind ◽

Severe Intensity ◽

Associated Symptoms ◽

Almost All

This randomized, double-blind, two-attack, placebo-controlled, crossover study explored the efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 50 mg as well as rizatriptan 5 mg compared with sumatriptan 25 mg in the acute treatment of migraine. Following randomization to one of six possible treatment sequences, patients ( n = 1447) treated two sequential attacks, of moderate or severe intensity, separated by at least 5 days. Patients assessed pain severity, migraine-associated symptoms, and functional disability at 0.5, 1, 1.5, and 2 h post treatment. Compared with placebo, all treatments were effective. On the primary endpoint of time to pain relief, rizatriptan 10 mg was not statistically different from sumatriptan 50 mg [odds ratio (OR) 1.10, P = 0.161], and rizatriptan 5 mg was statistically superior to sumatriptan 25 mg (OR 1.22, P = 0.007). In general, rizatriptan 10 mg and 5 mg treatment resulted in improvement compared with the corresponding doses of sumatriptan on measures of pain severity, migraine symptoms, and functional disability and the 5-mg dose reached statistical significance on almost all measures. All treatments were generally well tolerated.

Download Full-text